CDT stock plunges to 52-week low, hitting $3.21 amid steep decline

Murphy Canyon Acquisition Corp. (CDT) has hit a new 52-week low of $3.21, reflecting a 99.93% decline over the past year and a market capitalization of just $2.89 million; InvestingPro analysis indicates "WEAK" financial health with negative earnings yield and return on assets. Meanwhile, Conduit Pharmaceuticals Inc. announced compliance with Nasdaq listing standards, approved a 1-for-15 reverse stock split effective May 19, 2025, and reported progress in its autoimmune disease drug development, including securing patents and advancing clinical trials.

Analysis

Murphy Canyon Acquisition Corp. (CDT) is experiencing a severe downturn, with its stock hitting a new 52-week low of $3.21, plummeting its market capitalization to $2.89 million. This new low reflects a 99.93% destruction in stock value over the past year. According to InvestingPro analysis, the company exhibits "WEAK" overall financial health, underscored by a negative earnings yield of -7.29% and a deeply concerning return on assets of -317%. Although technical indicators such as RSI suggest CDT is in oversold territory, InvestingPro's analysis indicates the shares remain overvalued despite the significant price collapse. In separate developments, Conduit Pharmaceuticals Inc. has announced compliance with Nasdaq’s listing standards, specifically meeting the minimum bid price and stockholders’ equity requirements, which allows its securities to remain listed under a one-year Discretionary Panel Monitor. Conduit's board has also approved a 1-for-15 reverse stock split, effective May 19, 2025. Furthermore, Conduit reports progress in its research and development, including advancements in preclinical lupus studies, an upcoming Phase IIa clinical trial for its autoimmune disease drug candidates, and ongoing studies on glucokinase inhibitors with Charles River Laboratories, with results anticipated in Q2 2025. The company has also secured composition-of-matter patents for AZD1656 Cocrystals from regulatory bodies in Japan and Australia, with more approvals expected.

Key Decisions for Investors

• Investors should exercise extreme caution regarding Murphy Canyon Acquisition Corp. (CDT) due to its critical financial distress, near-complete erosion of shareholder value, negative earnings yield, and poor return on assets; the oversold RSI provides little comfort given the stock is still considered overvalued and has a 'WEAK' financial health score.
• For Conduit Pharmaceuticals, the achievement of Nasdaq compliance and ongoing R&D progress, including patent acquisitions and clinical trial advancements, are positive developments; however, the necessity of a reverse stock split and the oversight by a Nasdaq Discretionary Panel Monitor signal underlying risks that require careful monitoring of sustained compliance and future clinical outcomes.
• Potential investors must clearly distinguish between the highly distressed financial situation of Murphy Canyon Acquisition Corp. (CDT) and the distinct, developing scenario at Conduit Pharmaceuticals, which presents both opportunities in its R&D pipeline and risks associated with its financial stability and market listing.